Standard Biotools is trading at $0.79, up 6.36%, with no clear company announcement identified to explain the October 5 move.
- The latest company news located was its September 30 agreement to sell its Mass Cytometry business to Element Biosystems for $5.5 million.
- The broader market is higher: the S&P 500 is up 0.65% and the Nasdaq 1.00%. This supportive backdrop may be contributing, but a direct link to the stock’s gain is unconfirmed.